Rituximab in ANCA-associated vasculitis: Fad or fact?

Nephron - Clinical Practice

Volumn 118, Issue 2, 2011, Pages

  Fervenza, Fernando C ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

Cyclophosphamide; High dose glucocorticosteroids; Rituximab

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; EFALIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; NATALIZUMAB; PREDNISONE; RITUXIMAB;

ANCA ASSOCIATED VASCULITIS; B LYMPHOCYTE; CYSTITIS; DEATH; DRUG EFFICACY; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJECTION SITE REACTION; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; MAINTENANCE THERAPY; NEOPLASM; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHURG-STRAUSS SYNDROME; CLINICAL TRIALS AS TOPIC; HUMANS; WEGENER GRANULOMATOSIS;

EID: 78650072277     PISSN: 16602110     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000321437     Document Type: Review

References (62)

1. Jennette JC, Falk RJ, Andrassy K, et al: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-192.
2. Finkielman JD, Lee AS, Hummel AM, et al: ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med 2007; 120: 643.e9-e14.
3. Guillevin L, Cohen P, Gayraud M, et al: Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78: 26-37. (Pubitemid 29065978)
4. Guillevin L, Durand-Gasselin B, Cevallos R, et al: Microscopic polyangiitis: Clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42: 421-430. (Pubitemid 29136088)
5. Keogh KA, Specks U: Churg-Strauss syndrome: Clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003; 115: 284-290. (Pubitemid 37088190)
6. Fauci AS: Vasculitis. J Allergy Clin Immunol 1983; 72: 211-223. (Pubitemid 13005721)
7. Hoffman GS, Kerr GS, Leavitt RY, et al: Wegener granulomatosis: An analysis of 158 patients. Ann Intern Med 1992; 116: 488-498.
8. Fauci AS, Katz P, Haynes BF, Wolff SM: Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 1979; 301: 235-238. (Pubitemid 9234482)
9. Nachman PH, Hogan SL, Jennette JC, Falk RJ: Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7: 33-39. (Pubitemid 26067089)
10. Dorner T, Jacobi AM, Lipsky PE: B cells in autoimmunity. Arthritis Res Ther 2009; 11: 247.
11. Huugen D, Tervaert JW, Heeringa P: Antineutrophil cytoplasmic autoantibodies and pathophysiology: New insights from animal models. Curr Opin Rheumatol 2004; 16: 4-8. (Pubitemid 38041392)
12. Jennette JC, Xiao H, Falk RJ: Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol 2006; 17: 1235-1242. (Pubitemid 43673403)
13. Clayton AR, Savage CO: Production of antineutrophil cytoplasm antibodies derived from circulating B cells in patients with systemic vasculitis. Clin Exp Immunol 2003; 132: 174-179. (Pubitemid 36418921)
14. Popa ER, Stegeman CA, Bos NA, et al: Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 1999; 103: 885-894. (Pubitemid 29297593)
15. Stevenson HC, Fauci AS: Activation of human B lymphocytes. XII. Differential effects of in vitro cyclophosphamide on human lymphocyte subpopulations involved in Bcell activation. Immunology 1980; 39: 391-397. (Pubitemid 10120785)
16. Cupps TR, Edgar LC, Fauci AS: Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 1982; 128: 2453-2457. (Pubitemid 12124460)
17. Specks U, Fervenza FC, McDonald TJ, Hogan MC: Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001; 44: 2836-2840. (Pubitemid 34016203)
18. Keogh KA, Wylam ME, Stone JH, Specks U: Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 262-268. (Pubitemid 40129256)
19. Keogh KA, Ytterberg SR, Fervenza FC, et al: Rituximab for refractory Wegener's granulomatosis: Report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173: 180-187. (Pubitemid 43187890)
20. Leyendeckers H, Tasanen K, Bruckner-Tuderman L, et al: Memory B cells specific for the NC16A domain of the 180 kDa bullous pemphigoid autoantigen can be detected in peripheral blood of bullous pemphigoid patients and induced in vitro to synthesize autoantibodies. J Invest Dermatol 2003; 120: 372-378. (Pubitemid 36298422)
21. Cambridge G, Leandro MJ, Edwards JC, et al: Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48: 2146-2154. (Pubitemid 36959194)
22. De Vita S, Zaja F, Sacco S, et al: Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: Evidence for a pathogenetic role of B cells. Arthritis Rheum 2002; 46: 2029-2033.
23. Looney RJ, Anolik JH, Campbell D, et al: B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-2589. (Pubitemid 39062719)
24. Tamura N, Matsudaira R, Hirashima M, et al: Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. Intern Med 2007; 46: 409-414. (Pubitemid 46585484)
25. Stasi R, Stipa E, Del Poeta G, et al: Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 2006; 45: 1432-1436. (Pubitemid 44605482)
26. Ferraro AJ, Day CJ, Drayson MT, Savage CO: Effective therapeutic use of rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transplant 2005; 20: 622-625. (Pubitemid 40378435)
27. Eriksson P: Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005; 257: 540-548. (Pubitemid 40776514)
28. Maher LV, Wilson JG: Successful treatment of rheumatoid vasculitis-associated foot drop with rituximab. Rheumatology (Oxford) 2006; 45: 1450-1451. (Pubitemid 44605489)
29. Koukoulaki M, Smith KG, Jayne DR: Rituximab in Churg-Strauss syndrome. Ann Rheum Dis 2006; 65: 557-559.
30. Pepper RJ, Fabre MA, Pavesio C, et al: Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 2008; 47: 1104-1105. (Pubitemid 351865947)
31. Taylor SR, Salama AD, Joshi L, et al: Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009; 60: 1540-1547.
32. Smith KG, Jones RB, Burns SM, Jayne DR: Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006; 54: 2970-2982. (Pubitemid 44497778)
33. Jones RB, Ferraro AJ, Chaudhry AN, et al: A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody- associated vasculitis. Arthritis Rheum 2009; 60: 2156-2168.
34. Rhee EP, Laliberte KA, Niles JL: Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010; 5: 1394-1400.
35. Aries PM, Hellmich B, Voswinkel J, et al: Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006; 65: 853-858.
36. Omdal R, Wildhagen K, Hansen T, et al: Anti- CD20 therapy of treatment-resistant Wegener's granulomatosis: Favourable but temporary response. Scand J Rheumatol 2005; 34: 229-232. (Pubitemid 40978644)
37. Jones RB, Tervaert JW, Hauser T, et al: Rituximab versus cyclophosphamide in ANCAassociated renal vasculitis. N Engl J Med 2010; 363: 211-220.
38. Stone JH, Merkel PA, Spiera R, et al: Rituximab versus cyclophosphamide for ANCAassociated vasculitis. N Engl J Med 2010; 363: 221-232.
39. Merkel PA, Cuthbertson DD, Hellmich B, et al: Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Ann Rheum Dis 2009; 68: 103-106.
40. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 351-361.
41. Jayne D, Rasmussen N, Andrassy K, et al: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44. (Pubitemid 36765101)
42. Pagnoux C, Mahr A, Hamidou MA, et al: Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359: 2790-2803.
43. Rituxan warning. FDA Consum 2007; 41: 3.
44. Harris HE: Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab. Rheumatology (Oxford) 2008; 47: 224-225. (Pubitemid 351168240)
45. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA: Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus 2009; 18: 767-776.
46. Aksamit AJ: Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside. J Neurovirol 2001; 7: 386-390. (Pubitemid 32894247)
47. Choy DS, Weiss A, Lin PT: Progressive multifocal leukoencephalopathy following treatment for Wegener's granulomatosis. JAMA 1992; 268: 600-601.
48. Ettinger J, Feiden W, Hubner G, Schreiner M: Progressive multifocal leukoencephalopathy in Wegener's granulomatosis in relation to therapy with cyclosporin A (in German). Klin Wochenschr 1989; 67: 260-264. (Pubitemid 19057904)
49. Morgenstern LB, Pardo CA: Progressive multifocal leukoencephalopathy complicating treatment for Wegener's granulomatosis. J Rheumatol 1995; 22: 1593-1595.
50. Pagnoux C, Hayem G, Roux F, et al: JC virus leukoencephalopathy complicating Wegener's granulomatosis. Joint Bone Spine 2003; 70: 376-379. (Pubitemid 37243275)
51. Terrier B, Martinez V, Seilhean D, et al: Progressive multifocal leukoencephalopathy mimicking cerebral vasculitis in systemic granulomatosis. J Infect 2007; 54:e133-e135.
52. Wang HY: Pathologic quiz case: A 54-yearold deceased man with diffuse subcortical lesions of the central nervous system. Progressive multifocal leukoencephalopathy. Arch Pathol Lab Med 2004; 128:e70-e72.
53. Calabrese LH, Molloy ES, Huang D, Ransohoff RM: Progressive multifocal leukoencephalopathy in rheumatic diseases: Evolving clinical and pathologic patterns of disease. Arthritis Rheum 2007; 56: 2116-2128. (Pubitemid 47173558)
54. Manfro RC, Vedolin L, Cantarelli M, et al: Progressive multifocal leukoencephalopathy in a kidney transplant recipient after conversion to mycophenolic acid therapy. Transpl Infect Dis 2009; 11: 189-190.
55. Neff RT, Hurst FP, Falta EM, et al: Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 2008; 86: 1474-1478.
56. Tan CS, Koralnik IJ: Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: Clinical features and pathogenesis. Lancet Neurol 2010; 9: 425-437.
57. Major EO: Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010; 61: 35-47.
58. Slot MC, Tervaert JW, Boomsma MM, Stegeman CA: Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 2004; 51: 269-273. (Pubitemid 38468713)
59. Sanders JS, Huitma MG, Kallenberg CG, Stegeman CA: Prediction of relapses in PR3- ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology (Oxford) 2006; 45: 724-729. (Pubitemid 43985341)
60. Fervenza FC, Abraham RS, Erickson SB, et al: Rituximab therapy in idiopathic membranous nephropathy: A 2-year study. Clin J Am Soc Nephrol 2010, E-pub ahead of print.
61. Cartin-Ceba R, Golbin J, Keogh KA, et al: Rituximab for remission induction and maintenance in ANCA-associated vasculitis: A single-center ten-year experience in 108 patients. Arthritis & Rheum 2010;62:S283.
62. Fauci AS, Haynes BF, Katz P: Assessing treatments with cyclophosphamide (in comment). Ann Intern Med 1983; 98: 1026-1027.